OTS.at - aktuelle Inhalte in Text, Bild, Ton und Video

Grünenthal Group

Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors

Aachen (OTE) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive...

04.09.2025, 10:03:04
/
OTE0001

Grünenthal Group

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Aachen, Germany (OTE) - Aachen, Germany (ots)

02.06.2025, 10:00:33
/
OTE0002

Grünenthal Group

Maren Thurow starts as new Head Global Communications at Grünenthal

Aachen (OTE) - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department...

20.05.2025, 10:36:02
/
OTE0001

Grünenthal Group

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Aachen, Germany & Toronto, Canada, (OTE) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that...

24.02.2025, 15:44:17
/
OTE0001

Grünenthal Group

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

Aachen, Germany (OTE) - Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.

09.01.2025, 10:27:48
/
OTE0001

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neur

Aachen, Germany/Morristown, N.J. (OTE) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10...

07.11.2024, 10:39:32
/
OTE0001

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (OTE) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy...

22.10.2024, 12:13:17
/
OTE0001

Grünenthal Group

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

Aachen, Germany (OTE) - Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO)...

30.09.2024, 11:39:47
/
OTE0002

Grünenthal Group

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

Aachen, Germany (ots) - Grünenthal today announced the acquisition of US-based Valinor Pharma, LLC (“Valinor”) and its product Movantik® (naloxegol), with a total deal value of approx. $250 million inclusive...